ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade →

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.